Preferred Name |
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
Synonyms |
|
|
ID |
http://purl.bioontology.org/ontology/HCPCS/Q2042 |
|
cui |
C4724150 |
|
HAC |
N=No maintenance for this code |
|
HAD |
20190101 |
|
HAQ |
0 |
|
HBT |
O1E=Other drugs |
|
HCC |
C=Carrier judgment |
|
HCD |
20190101 |
|
HMP |
A=Not applicable as HCPCS priced under one methodology |
|
HPI |
51=Drugs |
|
HTS |
1=Medical care |
|
notation |
Q2042 |
|
prefLabel |
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
|
tui |
T200 |
|
subClassOf |
http://purl.bioontology.org/ontology/HCPCS/Level%202%3A%20Q2004-Q2056 |